Affordable Access

Publisher Website

Islet amyloid polypeptide:The cause of type-2 diabetes?

Authors
Journal
Trends in Endocrinology and Metabolism
1043-2760
Publisher
Elsevier
Publication Date
Volume
2
Issue
6
Identifiers
DOI: 10.1016/1043-2760(91)90025-i
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Islet amyloid polypeptide (IAPP or amylin), first identified as the peptide deposited as amyloid in type-2 diabetic pancreas and insulinoma, turns out to be a peptide produced in the pancreatic β-cell secretory granule that is costored and coreleased with insulin. Experimental evidence suggests that, under certain conditions, IAPP can counter insulin action in peripheral tissue and inhibit insulin release from the pancreas. IAPP therefore appears to respond to the same physiologic stimuli as insulin, but has opposing biologic actions. The role of IAPP, both in normal physiology and in pathology, remains unclear, but current evidence suggests against a role as a circulating hormone in favor of a paracrine or autocrine modulator of insulin secretion.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Islet amyloid polypeptide: the cause of type-2 dia...

on Trends in endocrinology and me... 1991

Islet amyloid polypeptide and type 2 diabetes

on Experimental Gerontology Jan 01, 2003

Islet amyloid polypeptide and type 2 diabetes.

on Experimental gerontology April 2003

Islet amyloid polypeptide is not a target antigen...

on Iranian journal of immunology... March 2014
More articles like this..